DOCSLIB.ORG

2017 NF CONFERENCE from Process to Progress

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
2017 NF CONFERENCE from Process to Progress END NF 2017 NF CONFERENCE From Process to Progress JUNE 10-13, 2017 | RENAISSANCE WASHINGTON, DC DOWNTOWN HOTEL Dear NF Conference Attendees: The Children’s Tumor Foundation strongly believes in collaboration—the kind that blossoms from meeting your peers, getting to know them, learning from them, and ultimately, connecting with them on a level that can only result from face-to-face interaction. Although the world of virtual communication—iPhones, Facebook, e-mail, Snapchat, Skype, Instagram (and much more)—has gained a lot of traction, I am an old-fashioned European who very much believes in authentic human connections. I am convinced that in order to build tangible, working collaborations and turn process into progress, trust is the ultimate key, and it is impossible to build trust with those you do not genuinely know. It is because of this principle that bringing those from the NF community together to mingle, share data, exchange knowledge, share projects and dreams, and simply enjoy one another’s company is very high on the Foundation’s priority list. This is what we aim to accomplish every year with the NF Conference, and this year in Washington, D.C. will be no exception! The Foundation is not alone in its gratitude for the annual NF Conference. At our Research Strategic Planning Retreat last fall, I was very happy to learn that a dynamic group of Board members and experts from both the NF community and other rare disease communities agreed that it should remain a top priority of the Foundation’s—and it will. Our conference is unique. Due to the heterogeneity of NF, it does not belong in one disease area, but in many, such as neurology, oncology, orthopedics, psychology, and many others. There is no other opportunity in the world for all of these diverse NF experts to meet and exchange their ideas, and to do so in an environment that encourages and cultivates these joint efforts. Although a number of collaborations in NF research began at the conference, we are particularly proud of Response Evaluation in Neurofibromatosis and Schwannomatosis (REiNS) getting its start at this remarkable forum. After having been a part the conference for over five years, I have pondered over the same interesting observation. Every year people tell me, ‘this was the best conference yet.’ We strive to make the conference the ‘best yet’ every year, and although it is indeed a costly operation, we are delighted to have the good fortune of reenergizing our NF community every year through this premier event. We cannot wait to see what this year has in store, and the fresh energy that it will bring! Lastly, don’t forget that next year we are crossing the Atlantic and bringing the NF Conference to Paris, France, an endeavor that is sure to give the conference the global presence it deserves. As the NF Conference itself expands, so will the amount of lives we change through our unwavering efforts to end NF around the globe. We are in D.C. today and Paris tomorrow, but we ceaselessly push the process and achieve progress as we search for the cure. Enjoy! ANNETTE BAKKER President and Chief Scientific Officer 2017 NF Conference · Washington, DC · June 10-13, 2017 | 3 CONTENTS Table of Contents INTRODUCTION The Friedrich von Recklinghausen Award: NF Tradition and Progress .......................................5 2017 Excellence in Team Science ...........................................................................................6 Foundation Staff .....................................................................................................................8 National Programs..................................................................................................................9 INFORMATION Schedule At-A-Glance ..........................................................................................................10 Important Notes To Chairs, Speakers & Poster Presenters .....................................................11 Agenda ................................................................................................................................12 Speaker Bios – Conference Chairs / Keynote Speakers ........................................................18 SPEAKER ABSTRACTS Abstracts .............................................................................................................................21 POSTER ABSTRACTS Basic Research ....................................................................................................................53 Clinical .................................................................................................................................78 ANCILLARY MEETINGS NF Clinics Breakout Session ...............................................................................................119 International Neurofibromatosis Autism Consortium Team (INFACT) ....................................120 APPENDIX Participants ........................................................................................................................122 Floor Plan ..........................................................................................................................126 City Map ............................................................................................................................127 Restaurant Guide ................................................................................................................128 Acknowledgements ............................................................................................................130 4 | Children’s Tumor Foundation · Ending Neurofibromatosis Through Research The Friedrich von Recklinghausen Award: Neurofibromatosis Tradition and Progress The Children’s Tumor Foundation’s Friedrich von Recklinghausen Award is given to individuals in the professional neurofibromatosis community who have made significant contributions to neurofibromatosis research or clinical care. It is named after Friedrich Daniel von Recklinghausen (1833-1910), the German physician who first described ‘von Recklinghausen’s disease’ – what we now know as neurofibromatosis type 1. 2017 Friedrich von Recklinghausen Award Recipient It is with great pleasure that the Children’s Tumor Foundation announces the 2017 recipient of the Friedrich von Recklinghausen Award, Karen Cichowski, PhD, Professor of Medicine at Harvard Medical School and Brigham and Women’s Hospital, and Chair and Scientific Director of the Neurofibromatosis Preclinical Consortium. Dr. Cichowski is a true thought leader in the neurofibromatosis field and has a longstanding record of excellence in NF1-related research, ranging from basic discoveries to translational output. Her lab has been focusing on understanding how NF1 functions on a cellular level in sporadic tumors, and tumors that develop in NF1 patients, and has leveraged this insight to suggest new targeted cancer therapies. She has also made major contributions to the field of NF1 tumorigenesis study, neurofibromin regulation, and the PCR2 complex. In addition, Dr. Cichowski has changed the field of NF research through her in depth studies of the RAS pathway and the discovery of a number of new negative feedback mechanisms. She showed that preclinical therapy of cancer in mice with a specific combination of targeted therapies affecting different consequences of RAS activation has a very strong therapeutic effect. Karen Cichowski has also been at the forefront of developing new therapies for the most devastating tumors associated with NF1: malignant peripheral nerve sheath tumors (MPNSTs). Her work has led to multiple clinical trials that are ongoing or under development, and has provided clarity on the biology of these aggressive tumors. This work has been fundamental to moving the field forward, and the paradigm of pre-clinical studies in her lab has provided an incredible framework for thinking about the partnership between basic and clinical research, which is a fundamental goal of the Children’s Tumor Foundation. The following are the most recent recipients of the Award: 2008 2009 2010 2012 2013 2014 2015 2016 Vincent ‘Vic’ Riccardi, Luis Parada, PhD, Nancy Ratner, PhD, David Gutmann, MD, Brigitte Widemann, MD Gareth Evans, MD Eric Legius, MD, PhD David Viskochil, MD, MD, University of Texas Cincinnati Children’s PhD, National Cancer St. Mary’s Hospital, University of Leuven, PhD The Neurofibromatosis Southwestern Hospital Medical Washington Institute U. of Manchester, UK Belgium University of Utah Institute Center University 2017 NF Conference · Washington, DC · June 10-13, 2017 | 5 2017 Excellence in Team Science Award In recognition of the value and impact of the Children’s Tumor Foundation’s growing portfolio of team science initiatives, we initiated the Excellence in Team Science Award in 2016, and we are thrilled to present this award again in 2017. Launched in 2014, Synodos for NF2 is a multi-year initiative that has assembled a team of researchers from twelve world-class labs and medical centers. This comprehensive, collaborative model brought together experts in basic, translational, and clinical research, who have joined forces to share information, free of bureaucratic obstacles and institutional competition. The most common medical issues were identified by NF2 patients, proposals were sought from the entire research community, and strategies that have a higher probability of finding solutions were designed. The brightest minds in the NF field are now working on these solutions
Load more

Recommended publications
  • Revision of Diagnostic Criteria for Neurofibromatosis
    Revision of Diagnostic Criteria for Neurofibromatosis Gareth Evans, MD, St. Mary’s Hospital/University of Manchester, UK Susan Huson, MD, Consultant Geneticist, UK Eric Legius, MD, PhD, University of Leuven, Belgium Ludwine Messiaen, PhD, University of AlaBama, Birmingham, USA Scott Plotkin, MD, PhD, Massachusetts General Hospital, USA Pierre Wolkenstein, MD, PhD, Hôpital Henri-Mondor, France 2019 NF Conference San Francisco, CA September 21, 2019 Revision of the Diagnostic Criteria of the Neurofibromatoses 92 medical specialists 20 countries 5 continents We want your feedback! Send email to: [email protected] Participants in revision process: Leadership team Clinical Epidemiology Health Services Research: Ophthalmology: • Gareth Evans • Nilton Rezende • Vanessa Merker • Robert Avery • Sue Huson • Catherine Cassiman • Eric Legius Clinical Genetics: Internal Medicine: Pathology: • Ludwine Messiaen • Dorothy Halliday • Luiz Oswaldo Carneiro • Karin Cunha • Scott Plotkin • Maurizio Clementi Rodrigues • Anat Stemmer-Rachamimov • Pierre Wolkenstein • Arvid Heiberg • Patrice Pancza • Joanne Ngeow Scientists: Pediatrics: • Shay Ben-Schachar • Miriam Smith • Outside Experts: • Bruce Korf • Marco Giovannini Rianne Oostenbrink • • Monique Anten • Mimi Berman • Eduard Serra Robert Listernick • Jaan Toelen • Betty Schorry • Juha Peltonen Pediatric Hematology and • Arthur Aylsworth • Gareth Evans Oncology: • Meredith Wilson • Ignacio Blanco Molecular Genetics: • Michael Fisher • Helen Hanson • Dusica Babovic-Vuksanovic •Laura Papi • Christopher
    [Show full text]
  • Palliative Care Clinical Academic Group Outcomes Book Outcomes
    King’s Health Partners | Palliative Care Clinical Academic Group Outcomes Book Outcomes Palliative Care Clinical Academic Group i King’s Health Partners King’s Health Partners brings together: n three of the UK’s leading NHS Foundation Trusts n a world-leading university for health research and education n nearly 4.8 million patient contacts each year n 40,000 staff n nearly 30,000 students n a combined annual turnover of more than £3.7 billion n services provided across central and south London and beyond, including nine mental health and physical healthcare hospitals and many community sites n a comprehensive portfolio of high-quality clinical services with international recognition in cancer, diabetes, mental health, regenerative medicine, transplantation, cardiac and clinical neurosciences n a major trauma centre and two hyper-acute stroke units King’s Health Partners | Palliative Care Clinical Academic Group Outcomes Book About King’s Health Partners King’s Health Partners brings together n Bring together our partnership’s collective a world-leading university for health research strength in a range of specialist services to and education, King’s College London and three deliver world-class patient care and research NHS Foundation Trusts Guy’s and St Thomas’, through our institutes programme; King’s College Hospital and South London and Maudsley. n Developing education, research and capacity building programmes in global We are an Academic Health Sciences Centre health including partnerships with healthcare where world-class research, education and teams and organisations in Sierra Leone, clinical practice are brought together to Somaliland and Zambia. benefit our patients.
    [Show full text]
  • 2018 Abstract Book
    CONTENTS Table of Contents INFORMATION Continuing Medical Education .................................................................................................5 Guidelines for Speakers ..........................................................................................................6 Guidelines for Poster Presentations .........................................................................................8 SPEAKER ABSTRACTS Abstracts ...............................................................................................................................9 POSTER ABSTRACTS Basic Research (Location – Room 101) ...............................................................................63 Clinical (Location – Room 8) ..............................................................................................141 2018 Joint Global Neurofibromatosis Conference · Paris, France · November 2-6, 2018 | 3 4 | 2018 Joint Global Neurofibromatosis Conference · Paris, France · November 2-6, 2018 EACCME European Accreditation Council for Continuing Medical Education 2018 Joint Global Neurofibromatosis Conference Paris, France, 02/11/2018–06/11/2018 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) for a maximum of 27 European CME credits (ECMEC®s). Each medical specialist should claim only those credits that he/she actually spent in the educational activity. The EACCME® is an institution of the European Union of Medical Specialists (UEMS), www.uems.net. Through an agreement between
    [Show full text]
  • Schwannomatosis: Tumors That Affect the Nervous System
    In partnership with Primary Children’s Hospital Schwannomatosis: Tumors that affect the nervous system Schwannomatosis (sh-WAHN-no-muh-TOH-siss) is a genetic What are the signs disorder that causes noncancerous (benign) tumors, of schwannomatosis? called schwannomas, to grow on the peripheral and Signs of schwannomatosis include: spinal nerves. These tumors can cause pain that are • Chronic pain anywhere in the body hard to control. (caused by schwannomas pushing on the nerves) One in 40,000 people worldwide develop • Numbness or tingling schwannomatosis, a rare form of neurofibromatosis (new-roh-FIBE-row-muh-TOH-siss) each year. • Headaches Neurofibromatosis is a group of genetic disorders • Vision changes that affect the nervous system. • Weakness (including facial weakness) What causes schwannomatosis? • Problems with bowel movements Because schwannomatosis is a genetic disorder, your child either: • Trouble urinating • Inherited an abnormal gene from a parent, or Your child may have mild or severe pain, and they • Inherited a gene mutation may not have other symptoms of schwannomatosis until later. This makes it hard to diagnose Many children who have schwannomatosis are the the disorder. first in their family to have symptoms of the disorder. However, these children can then pass How is schwannomatosis diagnosed? schwannomatosis to their own children. Your child’s healthcare provider will look at your child and ask questions about their pain and symptoms. Sometimes the provider may be able to feel a tumor during a physical exam,
    [Show full text]
  • DGCR8 Microprocessor Defect Characterizes Familial Multinodular Goiter with Schwannomatosis
    The Journal of Clinical Investigation CLINICAL MEDICINE DGCR8 microprocessor defect characterizes familial multinodular goiter with schwannomatosis Barbara Rivera,1,2,3 Javad Nadaf,2,3 Somayyeh Fahiminiya,4 Maria Apellaniz-Ruiz,2,3,4,5 Avi Saskin,5,6 Anne-Sophie Chong,2,3 Sahil Sharma,7 Rabea Wagener,8 Timothée Revil,5,9 Vincenzo Condello,10 Zineb Harra,2,3 Nancy Hamel,4 Nelly Sabbaghian,2,3 Karl Muchantef,11,12 Christian Thomas,13 Leanne de Kock,2,3,5 Marie-Noëlle Hébert-Blouin,14 Angelia V. Bassenden,15 Hannah Rabenstein,8 Ozgur Mete,16,17 Ralf Paschke,18,19,20,21,22 Marc P. Pusztaszeri,23 Werner Paulus,13 Albert Berghuis,15 Jiannis Ragoussis,4,9 Yuri E. Nikiforov,10 Reiner Siebert,8 Steffen Albrecht,24 Robert Turcotte,25,26 Martin Hasselblatt,13 Marc R. Fabian,1,2,3,7,15 and William D. Foulkes1,2,3,4,5,6 1Gerald Bronfman Department of Oncology, McGill University, Montreal, Quebec, Canada. 2Lady Davis Institute for Medical Research and 3Segal Cancer Centre, Jewish General Hospital, Montreal, Quebec, Canada. 4Cancer Research Program, McGill University Health Centre, Montreal, Quebec, Canada. 5Department of Human Genetics, McGill University, Montreal, Quebec, Canada. 6Division of Medical Genetics, Department of Medicine, McGill University Health Centre and Jewish General Hospital, Montreal, Quebec, Canada. 7Department of Experimental Medicine, McGill University, Montreal, Quebec, Canada. 8Institute of Human Genetics, University of Ulm and University of Ulm Medical Center, Ulm, Germany. 9Génome Québec Innovation Centre, McGill University, Montreal, Quebec, Canada. 10Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA. 11Department of Diagnostic Radiology, McGill University, Montreal, Quebec, Canada.
    [Show full text]
  • British Championships (50M) 2018
    British Summer Championships (50m) 2019 (Under FINA Technical Rules of Swimming and the British Swimming Judicial Code) DRAFT PROGRAMME Issue Eleven – Friday 5th July 2019 Tuesday 23rd July 2019 Session One – Heats – Start 9am EVENT 101 Mens 400m Freestyle 1. Charles Holyer 14 Fareham N'ds 4:26.38 ........ 60. Joshua Skinner 16 Nova Cent'n 4:11.28 ........ 2. Luke Critchlow 14 Stockport Mo 4:26.18 ........ 61. Michael Klimaszewski 15 Hatfield 4:11.23 ........ 3. Harry Wynne-Jones 14 Co Milton K 4:26.00 ........ 62. Harry Lewis-Mitchell 21 Edinburgh Un 4:10.91 ........ 4. Rico Bringeman 14 Boston 4:25.68 ........ 63. Samuel Neeld 19 Wrekin Coll 4:10.32 ........ 5. Harry Courtney 14 Tynedale 4:25.14 ........ 64. Lewis Binning 16 Basildon Ph 4:10.31 ........ 6. Lewis Cottam 14 Stockport Mo 4:24.76 ........ 65. Ethan Sutcliffe 16 Co Leeds 4:10.24 ........ 7. Liam Carey 14 Wigan BEST 4:24.72 ........ 66. Jack Watson 20 Edinburgh Un 4:10.10 ........ 8. Cillian McGuinness 14 Bassetlaw SS 4:23.63 ........ 67. Benjamin Prosser 19 Wycombe Dist 4:10.07 ........ 9. Curtis Harper 14 Co Sheffield 4:23.59 ........ 68. Dalton Clapham 16 Co Leeds 4:10.07 ........ 10. Cameron Carlos 14 Barnet Copt 4:23.43 ........ 69. Daniel Gencas 16 Romford Town 4:09.49 ........ 11. Joshua O Brien 14 Co Cardiff 4:23.08 ........ 70. Joseph Dobb 19 Bromley 4:09.45 ........ 12. Oliver Burns 14 Wolv'hampton 4:22.77 ........ 71. Charley Langford 16 Thanet Swim 4:09.35 ........ 13. Tyler Melbourne-Smith 14 Co Liverpool 4:22.54 .......
    [Show full text]
  • Westmoreland in the Late Seventeenth Century by Colin Phillips
    WESTMORLAND ABOUT 1670 BY COLIN PHILLIPS Topography and climate This volume prints four documents relating to the hearth tax in Westmorland1. It is important to set these documents in their geographical context. Westmorland, until 1974 was one of England’s ancient counties when it became part of Cumbria. The boundaries are shown on map 1.2 Celia Fiennes’s view in 1698 of ‘…Rich land in the bottoms, as one may call them considering the vast hills above them on all sides…’ was more positive than that of Daniel Defoe who, in 1724, considered Westmorland ‘A country eminent only for being the wildest, most barren and frightful of any that I have passed over in England, or even Wales it self. ’ It was a county of stark topographical contrasts, fringed by long and deep waters of the Lake District, bisected by mountains with high and wild fells. Communications were difficult: Helvellyn, Harter Fell, Shap Fell and the Langdale Fells prevented easy cross-county movement, although there were in the seventeenth century three routes identified with Kirkstone, Shap, and Grayrigg.3 Yet there were more fertile lowland areas and 1 TNA, Exchequer, lay subsidy rolls, E179/195/73, compiled for the Michaelmas 1670 collection, and including Kendal borough. The document was printed as extracts in W. Farrer, Records relating to the barony of Kendale, ed. J. F. Curwen (CWAAS, Record Series, 4 & 5 1923, 1924; reprinted 1998, 1999); and, without the exempt, in The later records relating to north Westmorland, ed. J. F. Curwen (CWAAS, Record Series, 8, 1932); WD/Ry, box 28, Ms R, pp.1-112, for Westmorland, dated 1674/5, and excluding Kendal borough and Kirkland (heavily edited in J.
    [Show full text]
  • New Frontiers
    PROGRAM & BOOK OF ABSTRACTS JUNE 13-16, 2009 • PORTLAND, OREGON New Frontiers Children’s Tumor FoundaTION 95 PINE STREET, 16TH FLOOR, NEW YORK, NY 10005 | WWW.CTF.ORG | 212.344.6633 Dear NF Conference Attendees: On behalf of the Children’s Tumor Foundation, welcome to the 2009 NF Conference: New Frontiers. The theme references the meeting content and also Portland itself, historically a gateway port of the Pacific North West. The urban setting offers a ‘new frontier’ in comparison to the mountain and beach locales of past NF Conferences, but one which we feel you will enjoy. Portland is an easy-going city offering history, beauty and relaxation – features encapsulated in our host hotel The Nines, itself a part of the tapestry of Portland history, renovated from the former landmark Meier & Frank department store. The last year has seen major NF research advances. The dovetailing of discovery, translation and the clinic can be seen throughout the meeting. We are firmly in the age of NF clinical trials and proud that the Children’s Tumor Foundation is part of this advance: in 2009 we funded our first two pilot Clinical Trial Awards. We continue to build a pipeline of candidate NF drug therapies through the Foundation’s multi-center NF Preclinical Consortium and the seed grant Drug Discovery Initiative (DDI) program. Through these translational initiatives we are cultivating NF collaborations with the biotechnology and pharmaceutical sector, a critical factor in moving NF research forward to the clinic. At the same time, basic research advances continue, such as in the unraveling of schwannomatosis.
    [Show full text]
  • Newly Diagnosed with Schwannomatosis: a Guide to the Basics
    NEWLY DIAGNOSED WITH SCHWANNOMATOSIS: A GUIDE TO THE BASICS ctf.org 1-800-323-7938 CONTENTS Newly Diagnosed? You Are Not Alone 2 The Children’s Tumor Foundation 4 NF Basics 5 Understanding Schwannomatosis Symptoms 6 Inheritance and Genetics of Schwannomatosis 7 How Is the Diagnosis Made? 10 Medical Management of Schwannomatosis 11 Sharing the News 13 Connecting with Other Patients and Families 15 Schwannomatosis Research 16 Insurance Coverage for Schwannomatosis 17 Resources 18 NEWLY DIAGNOSED? You Are Not Alone We at the Children’s Tumor Foundation (CTF) understand that many questions and concerns arise after receiving a diagnosis of schwannomatosis, a form of neurofibromatosis, or NF. There’s a lot of information to absorb at one time, and you probably want to know how your diagnosis will impact your life. It can be helpful to remember that different people may deal with health-related news in different ways. While some prefer to digest small bits of information at a time, others like to get as much information as possible right away. Both of these approaches are perfectly normal. It’s important to know that the symptoms of schwannomatosis vary widely, and most people with the condition continue to lead full and active lives under the care of an experienced specialist who can manage their symptoms and watch for potential complications. This brochure is designed to give you essential information about schwannomatosis as well as provide key advice and resources so that you can take care of your health and continue to get the most out of life. 2 As you begin your journey of learning more about schwannomatosis, we also want you to know that you are not alone.
    [Show full text]
  • C-Fiber Loss As a Possible Cause of Neuropathic Pain in Schwannomatosis
    International Journal of Molecular Sciences Article C-Fiber Loss as a Possible Cause of Neuropathic Pain in Schwannomatosis 1, , 2,3 4 1 Said C. Farschtschi * y , Tina Mainka , Markus Glatzel , Anna-Lena Hannekum , Michael Hauck 1,5, Mathias Gelderblom 1, Christian Hagel 4 , Reinhard E. Friedrich 6, Martin U. Schuhmann 7, Alexander Schulz 8,9, Helen Morrison 8, Hildegard Kehrer-Sawatzki 10, 1 1 11 11,12, Jan Luhmann , Christian Gerloff , Martin Bendszus , Philipp Bäumer z and 1, Victor-Felix Mautner z 1 Department of Neurology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany; [email protected] (A.-L.H.); [email protected] (M.H.); [email protected] (M.G.); [email protected] (J.L.); gerloff@uke.de (C.G.); [email protected] (V.-F.M.) 2 Department of Neurology, Charité University Medicine, 10117 Berlin, Germany; [email protected] 3 Berlin Institute of Health, 10178 Berlin, Germany 4 Department of Neuropathology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany; [email protected] (M.G.); [email protected] (C.H.) 5 Department of Neurophysiology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany 6 Department of Maxillofacial Surgery, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany; [email protected] 7 Department of Neurosurgery, University Medical Center Tübingen, 72076 Tübingen, Germany; [email protected] 8 Leibniz Institute on Aging, Fritz Lipmann Institute, 07745 Jena, Germany; [email protected] (A.S.); helen.morrison@leibniz-fli.de (H.M.) 9 MVZ Human Genetics, 99084 Erfurt, Germany 10 Institute of Human Genetics, University of Ulm, 89081 Ulm, Germany; [email protected] 11 Department of Neuroradiology, University Medical Center Heidelberg, 69120 Heidelberg, Germany; [email protected] (M.B.); [email protected] (P.B.) 12 Department of Radiology, German Cancer Research Center, 69120 Heidelberg, Germany * Correspondence: [email protected]; Tel.: +49(0)407410-53869 Martinistr.
    [Show full text]
  • Durham E-Theses
    Durham E-Theses The history and development of Catholic education in the North and East ridings of Yorkshire and the city of York from 1571 to 1870 Kitching, Jack How to cite: Kitching, Jack (1956) The history and development of Catholic education in the North and East ridings of Yorkshire and the city of York from 1571 to 1870, Durham theses, Durham University. Available at Durham E-Theses Online: http://etheses.dur.ac.uk/10262/ Use policy The full-text may be used and/or reproduced, and given to third parties in any format or medium, without prior permission or charge, for personal research or study, educational, or not-for-prot purposes provided that: • a full bibliographic reference is made to the original source • a link is made to the metadata record in Durham E-Theses • the full-text is not changed in any way The full-text must not be sold in any format or medium without the formal permission of the copyright holders. Please consult the full Durham E-Theses policy for further details. Academic Support Oce, Durham University, University Oce, Old Elvet, Durham DH1 3HP e-mail: [email protected] Tel: +44 0191 334 6107 http://etheses.dur.ac.uk 2 THE HISTORY MD DEVELOPMENT OF CATHOLIC EDUCATION IN THE NORTH AND EAST RIDINGS OF YORKSHIRE AND THE CITY OF YORK FROM 1571 to 1870 A Thesis Presented for the Degree of Master of Education at The University of Durham by Jack Kitching March 1956 . The copyright of this thesis rests with the author.
    [Show full text]
  • Current Understanding of Neurofibromatosis Type 1, 2, And
    International Journal of Molecular Sciences Review Current Understanding of Neurofibromatosis Type 1, 2, and Schwannomatosis Ryota Tamura Department of Neurosurgery, Kawasaki Municipal Hospital, Shinkawadori, Kanagawa, Kawasaki-ku 210-0013, Japan; [email protected] Abstract: Neurofibromatosis (NF) is a neurocutaneous syndrome characterized by the development of tumors of the central or peripheral nervous system including the brain, spinal cord, organs, skin, and bones. There are three types of NF: NF1 accounting for 96% of all cases, NF2 in 3%, and schwannomatosis (SWN) in <1%. The NF1 gene is located on chromosome 17q11.2, which encodes for a tumor suppressor protein, neurofibromin, that functions as a negative regulator of Ras/MAPK and PI3K/mTOR signaling pathways. The NF2 gene is identified on chromosome 22q12, which encodes for merlin, a tumor suppressor protein related to ezrin-radixin-moesin that modulates the activity of PI3K/AKT, Raf/MEK/ERK, and mTOR signaling pathways. In contrast, molecular insights on the different forms of SWN remain unclear. Inactivating mutations in the tumor suppressor genes SMARCB1 and LZTR1 are considered responsible for a majority of cases. Recently, treatment strategies to target specific genetic or molecular events involved in their tumorigenesis are developed. This study discusses molecular pathways and related targeted therapies for NF1, NF2, and SWN and reviews recent clinical trials which involve NF patients. Keywords: neurofibromatosis type 1; neurofibromatosis type 2; schwannomatosis; molecular tar- geted therapy; clinical trial Citation: Tamura, R. Current Understanding of Neurofibromatosis Int. Type 1, 2, and Schwannomatosis. 1. Introduction J. Mol. Sci. 2021, 22, 5850. https:// doi.org/10.3390/ijms22115850 Neurofibromatosis (NF) is a genetic disorder that causes multiple tumors on nerve tissues, including brain, spinal cord, and peripheral nerves [1–3].
    [Show full text]